Insitro
Founded Year
2018Stage
Series C | AliveTotal Raised
$643MLast Raised
$400M | 4 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+52 points in the past 30 days
About Insitro
Insitro focuses on drug discovery and development. The company's main services involve the use of machine learning and throughput biology to predict successful paths for medicine creation. It aims to avoid costly failures in pharmaceutical research and development. Insitro primarily sells to the healthcare industry. It was founded in 2018 and is based in South San Francisco, California.
Loading...
Insitro's Products & Differentiators
Statistical genetics
ML-enabled statistical genetics to discover targets and patient segments
Loading...
Research containing Insitro
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Insitro in 4 CB Insights research briefs, most recently on Mar 11, 2025.
Expert Collections containing Insitro
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Insitro is included in 7 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,270 items
AI 100
200 items
Digital Health 50
300 items
The most promising digital health startups transforming the healthcare industry
Digital Health
11,306 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Artificial Intelligence
7,221 items
Insitro Patents
Insitro has filed 26 patents.
The 3 most popular patent topics include:
- biotechnology
- molecular biology
- genetics
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/24/2024 | 3/25/2025 | Genetics, Rare diseases, Molecular biology, Autoimmune diseases, Recommender systems | Grant |
Application Date | 4/24/2024 |
|---|---|
Grant Date | 3/25/2025 |
Title | |
Related Topics | Genetics, Rare diseases, Molecular biology, Autoimmune diseases, Recommender systems |
Status | Grant |
Latest Insitro News
Mar 19, 2025
Among these are optical coherence tomography (OCT) images, connected to decades of clinical info encompassing chronic metabolic, neurodegenerative and ophthalmic disorders related to ageing. The AI model will support Insitro’s neuroscience programmes, focusing on detecting OCT-based signatures related to the risk and progression of dementia. Moorfields Eye Hospital, as part of National Health Service (NHS), gathers a significant volume of OCT images prior to a diagnosis of dementia. It expedites insitro’s offerings in discovering biological targets backed by human genetics. This collection is crucial to develop a model to distinguish between the OCTs of individuals who develop this condition and those who do not. The scale of the OCT images, combined with dementia diagnosis data, will facilitate the creation of a quality model for insitro’s drug discovery initiatives. insitro founder and CEO Daphne Koller stated: “OCT data at this scale contains a treasure trove of information about human health, providing a new window into diseases of the brain, the eye and more. “Building a world-class foundation model with Insight at Moorfields will help us unravel disease biology and identify novel targets, including for our programmes in neurodegenerative diseases.” The combined effort is set to leverage the Insight-developed eye research data infrastructure at Moorfields, which has been instrumental in the field of Oculomics. Foundation models are adaptable across multiple tasks ,eliminating the requirement for task-specific training from the ground up.
Insitro Frequently Asked Questions (FAQ)
When was Insitro founded?
Insitro was founded in 2018.
Where is Insitro's headquarters?
Insitro's headquarters is located at 279 East Grand Avenue, South San Francisco.
What is Insitro's latest funding round?
Insitro's latest funding round is Series C.
How much did Insitro raise?
Insitro raised a total of $643M.
Who are the investors of Insitro?
Investors of Insitro include Third Rock Ventures, Two Sigma Ventures, Andreessen Horowitz, Alexandria Venture Investments, Foresite Capital and 15 more.
Who are Insitro's competitors?
Competitors of Insitro include Atomwise, Noetik, BioSymetrics, Exscientia, Turbine and 7 more.
What products does Insitro offer?
Insitro's products include Statistical genetics and 2 more.
Loading...
Compare Insitro to Competitors
Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.
Healx is a technology company focused on artificial intelligence (AI) drug discovery for rare disease treatment within the pharmaceutical industry. The company specializes in using AI to identify drug-disease relationships and accelerate the development of new therapies for rare conditions. Healx's approach aims to increase the scale and success rate of rare disease treatment development by repurposing known compounds and running multiple drug discovery programs in parallel. Healx was formerly known as Healx3. It was founded in 2014 and is based in Cambridge, United Kingdom.
Aria Pharmaceuticals operates as a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small-molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using its proprietary symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.
Standigm specializes in AI-driven drug discovery within the pharmaceutical industry. The company provides services, including target identification, lead generation, and optimization, as well as AI SaaS solutions for drug development. Standigm primarily serves sectors engaged in pharmaceutical research and drug development. It was founded in 2015 and is based in Seoul, South Korea.
Aitia focuses on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. It is used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.
Insilico Medicine focuses on artificial intelligence in drug discovery and development. The company provides artificial intelligence (AI) platforms for multi-omics target discovery, deep biology analysis, automated drug design, and predicting outcomes in clinical trials. The technologies are intended to assist in the process of discovering and developing new medications for various diseases. It was founded in 2014 and is based in New Territories, Hong Kong.
Loading...